Inventiva Förvaltning

Förvaltning kriterier kontrolleras 1/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

Andrew Obenshain

Verkställande direktör

€10.8m

Total ersättning

VD-lön i procent	1.41%
Anställning som VD	less than a year
Ägande av VD	n/a
Ledningens genomsnittliga anställningstid	less than a year
Styrelsens genomsnittliga mandatperiod	6.1yrs

Senaste uppdateringar av ledningen

Recent updates

Seeking Alpha • May 15

Inventiva's Speculative Upside Through MASH Is Promising

Summary Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV3 readout, which we should get by Q4 2026. In my view, lanifibranor seems relatively differentiated after its Phase 2b results. Management is narrowing its focus solely on this MASH asset. IVA’s balance sheet has sufficient financing to reach that readout. But please bear in mind that it’s a binary outcome. I believe that, if lanifibranor succeeds, the upside could be considerable. Conversely, if they fail, their runway would be tighter with a failed asset. On balance, IVA is the quintessential high-risk, high-reward biotech stock. But, given its promising trial data, the setup is compelling. Read the full article on Seeking Alpha

Seeking Alpha • Jul 08

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Summary Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was conducted, and it was noted that the phase 3 NATiV3 study should continue without modification. The global non-alcoholic steatohepatitis market is expected to reach $48.3 billion by the end of 2035. It could compete against other MASH companies with the use of lanifibranor by establishing several competitive advantages or by combining it with GLP-1 drugs. Read the full article on Seeking Alpha

Seeking Alpha • Feb 22

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Summary Enrollment pause in phase III NATiV3 study, using lanifibranor for the treatment of patients with NASH, only expected to last 4 to 6 weeks; Trial to continue on with protocol amendments. Publication of results from phase IIa LEGEND study, using lanifibranor in combination with Jardiance for the treatment of patients with NASH and Type 2 Diabetes, expected Q1 of 2024. The global non-alcoholic steatohepatitis treatment market size is expected to reach $48.3 billion by the end of 2035. Several competitors in NASH, but the company might overcome most with the fact that oral administration can be given; Another option to beat the competition would be through combination treatments such as lanifibranor + Jardiance. Read the full article on Seeking Alpha

Seeking Alpha • Sep 21

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

France-based clinical-stage biopharma Inventiva (NASDAQ:IVA) on Wednesday said it had entered into a licensing and collaboration agreement with a unit of Chinese pharmaceutical group Sino Biopharm for its non-alcoholic steatohepatitis (NASH) treatment lanifibranor. As per the deal, Inventiva (IVA) will get a $12M upfront payment along with $5M in short term potential milestone payments. IVA will also be eligible to get up to $290M in clinical, regulatory and commercial milestone payments, in addition to tiered royalties. Sino Biopharm will oversee the development and commercialization of lanifibranor in Greater China, IVA said in a statement. IVA's lanifibranor had previously received a breakthrough therapy designation from the U.S. FDA. U.S.-listed shares of IVA -2.8% to $3.82 after hours.

Analys av ersättningar till VD

Hur har Andrew Obenshain:s ersättning förändrats jämfört med Inventiva:s resultat?
Datum	Total ersättning	Lön	Företagets resultat
Dec 31 2025	€11m	€152k	-€354m

Ersättning vs marknad: Andrew s total kompensation ($USD 12.61M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 3.70M ).

Ersättning vs inkomst: Otillräcklig data för att jämföra Andrew s ersättning med företagets resultat.

VD OCH KONCERNCHEF

Andrew Obenshain (50 yo)

less than a year

Anställning

€10,832,244

Kompensation

Mr. Andrew Obenshain serves as Chief Executive Director at Inventiva S.A. since October 01, 2025 and served as its Director. He has been the Director of bluebird bio, Inc. since November 2021 and served as...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Andrew Obenshain	Chief Executive Officer	less than a year	€10.83m	inga uppgifter
Pierre Broqua	Co-Founder	15.3yrs	€411.80k	1.65% $ 18.5m
Jean Volatier	Executive VP Finance & Corporate Social Responsibility	less than a year	€1.47m	0.11% $ 1.2m
Martine Zimmermann	Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs	less than a year	€4.19m	inga uppgifter
Jason Campagna	President of Research & Development and Chief Medical Officer	less than a year	€2.82m	inga uppgifter
Axel-Sven Malkomes	Chief Financial Officer	less than a year	inga uppgifter	inga uppgifter
Susan Coles	Chief Legal Officer	less than a year	inga uppgifter	inga uppgifter
Pamela Herbster	Chief People Officer	less than a year	inga uppgifter	inga uppgifter
Pascaline Clerc	Executive Vice President of External and Corporate Affairs	2.6yrs	inga uppgifter	0.0088% $ 98.5k
Nazira Amra	Chief Commercial Strategy Officer	no data	inga uppgifter	inga uppgifter

0.6yrs

Genomsnittlig anställningstid

58yo

Genomsnittlig ålder

Erfaren ledning: IVA s ledningsgrupp anses inte vara erfaren ( 0.6 års genomsnittlig anställningstid), vilket föreslår ett nytt team.

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Mark Pruzanski	Independent Chairman	1.4yrs	€14.42m	inga uppgifter
Annick Schwebig	Independent Director	9.3yrs	€141.90k	0.0015% $ 16.6k
Jean-Louis Junien	Chairman of Scientific Advisory Board	no data	€16.00k	inga uppgifter
Andrew Shenker	Member of Scientific Advisory Board	6.5yrs	inga uppgifter	inga uppgifter
Arun Sanyal	Member of Scientific Advisory Board	5.8yrs	inga uppgifter	inga uppgifter
Heinz Maeusli	Independent Director	7yrs	€135.60k	inga uppgifter
Sven Francque	Member of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Manal Abdelmalek	Member of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Kenneth Cusi	Member of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Glen Clack	Member of Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Gérard Zalcman	Scientific Advisory Board Member	no data	inga uppgifter	inga uppgifter
Elisabetta Bugianesi	Member of the Scientific Advisory Board	4.3yrs	inga uppgifter	inga uppgifter

6.1yrs

Genomsnittlig anställningstid

70yo

Genomsnittlig ålder

Erfaren styrelse: IVA s styrelse anses vara erfaren ( 6.1 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/26 18:14
Aktiekurs vid dagens slut	2026/05/22 00:00
Intäkter	2025/12/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Inventiva S.A. bevakas av 23 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Eliana Merle	Barclays
Edward Nash	Canaccord Genuity
Etzer Darout	Guggenheim Securities, LLC

Inventiva Förvaltning

Förvaltning kriterier kontrolleras 1/4

Viktig information

Senaste uppdateringar av ledningen

Inventiva S.A., Annual General Meeting, Jun 30, 2026

Inventiva Announces Executives Changes

Inventiva Announces CEO Changes

Inventiva Announces Executive Appointments

Inventiva Announces the Appointment of Renée Aguiar-Lucander to Its Board of Directors

Inventiva S.A., Annual General Meeting, May 22, 2025

Recent updates

Inventiva S.A., Annual General Meeting, Jun 30, 2026

Inventiva's Speculative Upside Through MASH Is Promising

Inventiva Announces Executives Changes

Inventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million.

Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million.

Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million.

Inventiva Announces CEO Changes

Inventiva Announces Executive Appointments

Inventiva Announces the Publication in Journal of Hepatology Reports on Results of Lanifibranor Treatment on Liver Sinusoidal Endothelial Cells in Patients with MASLD/MASH and in Preclinical Models of the Disease

Inventiva Announces the Appointment of Renée Aguiar-Lucander to Its Board of Directors

Inventiva Announces the Publication in Clinical Gastroenterology and Hepatology of Its Analysis of New Biomarker Signatures Predictive of Histological Response in Patients with Mash Treated with Lanifibranor

Inventiva S.A., Annual General Meeting, May 22, 2025

Inventiva S.A. and Hepalys Pharma, Inc. Announce the Initiation of the Clinical Development Program of Lanifibranor in Japan

Inventiva S.A. to Report First Half, 2025 Results on Sep 25, 2025

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis